Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.

McKinney RE Jr, Rodman J, Hu C, Britto P, Hughes M, Smith ME, Serchuck LK, Kraimer J, Ortiz AA, Flynn P, Yogev R, Spector S, Draper L, Tran P, Scites M, Dickover R, Weinberg A, Cunningham C, Abrams E, Blum MR, Chittick GE, Reynolds L, Rathore M; Pediatric AIDS Clinical Trials Group Protocol P1021 Study Team..

Pediatrics. 2007 Aug;120(2):e416-23.

PMID:
17646352
2.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
3.

Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy.

Cahn P.

Expert Opin Investig Drugs. 2004 Jan;13(1):55-68. Review.

PMID:
14680453
4.

Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.

Palacios R, Aguilar I, Hidalgo A, Santos J.

Expert Rev Anti Infect Ther. 2006 Dec;4(6):965-71. Review.

PMID:
17181413
5.

An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients.

Putcharoen O, Kerr SJ, Ruxrungtham K.

HIV AIDS (Auckl). 2013 Sep 16;5:231-41. doi: 10.2147/HIV.S25712. Review.

6.
7.

Efavirenz-induced hypersensitivity reaction manifesting in rash and hepatitis in a Latino male.

Leung JM, O'Brien JG, Wong HK, Winslow DL.

Ann Pharmacother. 2008 Mar;42(3):425-9. doi: 10.1345/aph.1K574. Review.

PMID:
18252833
8.

A systematic review of the psychiatric side-effects of efavirenz.

Kenedi CA, Goforth HW.

AIDS Behav. 2011 Nov;15(8):1803-18. doi: 10.1007/s10461-011-9939-5. Review.

PMID:
21484283
9.
Items per page

Supplemental Content

Support Center